Show simple item record

dc.contributor.editorJeon, Byeong Hwa
dc.date.accessioned2022-05-06T11:22:13Z
dc.date.available2022-05-06T11:22:13Z
dc.date.issued2022
dc.identifierONIX_20220506_9783036530369_87
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/81021
dc.description.abstractDear colleagues, This Special Issue, “Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches”, focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions. Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment. The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host–immune reactions near tumor environments.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issuesen_US
dc.subject.classificationthema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TC Biochemical engineering::TCB Biotechnologyen_US
dc.subject.otherendothelial cells
dc.subject.otheroxidative stress
dc.subject.otherinflammageing
dc.subject.otherendothelial dysfunction
dc.subject.otheraldehyde dehydrogenase-2
dc.subject.othercardiovascular disease
dc.subject.otherneurovascular disease
dc.subject.othervascular inflammation
dc.subject.otherAPE1/Ref-1
dc.subject.othercardiovascular diseases
dc.subject.othersubcellular localization
dc.subject.otherserological biomarkers
dc.subject.otheratherosclerosis
dc.subject.otheraerobic exercise
dc.subject.otherPCSK9
dc.subject.otherLOX-1
dc.subject.otherinsulin resistance
dc.subject.othermacrophage polarity
dc.subject.otherserum γ-glutamyltransferase
dc.subject.otheressential hypertension
dc.subject.othercardiovascular risk factors
dc.subject.otherangiogenesis
dc.subject.othernargenicin A1
dc.subject.othercompound 9
dc.subject.otherVEGF
dc.subject.otherVEGFR2
dc.subject.otherHIF-1α
dc.subject.otherelectronegative low-density lipoprotein
dc.subject.otherLDL(–)
dc.subject.otherL5 LDL
dc.subject.otheroxidized LDL
dc.subject.otheroxLDL
dc.subject.otherADMA
dc.subject.otherarginine
dc.subject.otherarginine paradox
dc.subject.otherBH4
dc.subject.otherblood pressure
dc.subject.otherCOVID-19
dc.subject.otherdietary supplements
dc.subject.otherendothelium
dc.subject.othereNOS uncoupling
dc.subject.otherheart failure
dc.subject.otherhypertension
dc.subject.otherL-arginine
dc.subject.othermyocardial infarction
dc.subject.otherNADPH
dc.subject.othernitric oxide
dc.subject.otherperipheral artery disease
dc.subject.otherApoE knockout mouse
dc.subject.otheratorvastatin
dc.subject.otherVCAM-1
dc.subject.othergalectin-3
dc.subject.otherneutrophil/lymphocyte ratio
dc.subject.otherelectronegative LDL
dc.subject.otherLDL(−)
dc.subject.otherlectin-like oxLDL receptor-1
dc.subject.otherdyslipidemia
dc.subject.otherchronic venous insufficiency
dc.subject.otherprolyl oligopeptidase (POP)
dc.subject.otherinflammation
dc.subject.otherendothelial disfunction
dc.subject.otherlung disease
dc.subject.otherendothelial to mesenchymal transition
dc.subject.otherpulmonary hypertension
dc.subject.otherpulmonary fibrosis
dc.subject.othermetformin
dc.subject.otherdiabetes
dc.subject.otherCV risk
dc.subject.otherhyperglycemia
dc.subject.otherglycated lipoproteins
dc.subject.otherglycated LDL
dc.subject.otherglycated HDL
dc.subject.otherendothelial cell dysfunction
dc.subject.othermolecular mechanisms
dc.subject.otherepigenetic factors
dc.subject.othertherapeutic approaches
dc.subject.othervasoactive factors
dc.subject.otherEndoMT
dc.subject.otherTGF-β
dc.subject.otherepigenetics
dc.subject.otherendothelial cell
dc.subject.otherglycolysis
dc.subject.othermetabolism
dc.subject.otherpathological angiogenesis
dc.subject.othertumor microenvironment
dc.subject.otherMRI (magnetic resonance imaging)
dc.subject.otherhigh-fat diets
dc.subject.otherplaque burden
dc.subject.otherlow-level laser therapy
dc.subject.otherphototherapy
dc.subject.othervascular disease
dc.subject.otherhealing
dc.subject.otherischemia
dc.subject.othervascular calcification
dc.subject.otherchronic kidney disease
dc.subject.otherCKD
dc.subject.otheruremic toxins
dc.subject.otherhyperphosphatemia
dc.subject.othervascular smooth muscle cells
dc.subject.otherVSMCs
dc.subject.othermacrophages
dc.subject.othern/a
dc.titleEndothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-3037-6
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036530369
oapen.relation.isbn9783036530376
oapen.pages368
oapen.place.publicationBasel


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/